4- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamide

07/01/1993 - "In summary, the results of our study indicate that compound NO-1886 increases LPL activity, causing an elevation in HDL levels, and that long-term administration of NO-1886 to rats with experimental atherosclerosis provides significant protection against the development of coronary artery lesions."
01/01/2002 - "Furthermore, NO-1886 provided protection against the development of atherosclerosis in the aorta. "
09/01/2006 - "These results demonstrate that the mechanism of atherosclerosis inhibition for NO-1886 is associated with its effect on ABCA1."
09/01/2006 - "However, the mechanism of atherosclerosis inhibition for NO-1886 is not fully understood. "
09/01/2006 - "NO-1886 has been proven to be highly effective at increasing HDL-C and reducing atherosclerosis. "

03/01/2004 - "Therefore, NO-1886 is potentially beneficial for the treatment of insulin-resistance syndrome."
01/01/2003 - "In the current study, we investigated the effects of NO-1886 on insulin resistance and beta-cell function in rabbits. "
01/01/2010 - "NO-1886, a chemically synthesized lipoprotein lipase activator, suppresses diet-induced insulin resistance with the improvement of HDL-C. "
01/01/2010 - "NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1."
07/01/2000 - "A high-fat diet induced wholebody insulin resistance (clamp glucose infusion rate: 4.8 +/- 1.3 mg x kg(-1) x min(-1) vs 10.6 +/- 1.1 for the chow group, p < 0.01) with NO-1886 lessening this effect (8.3 +/- 0.5, p < 0.05 vs high-fat). "

02/22/2005 - "In this study, therefore, the effects of NO-1886 on hyperlipidemia and intestinal polyp formation were investigated in Min mice. "
02/22/2005 - "Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice."
12/01/1996 - "Suppression of hyperlipidemia-associated cataracts in diabetic rats with the lipoprotein lipase activator NO-1886."
05/01/2000 - "The aim of this study was to ascertain whether NO-1886 suppresses the renal injury by treatment of the hyperlipidemia in an Adriamycin (Kyowa Hakko Kogyo, Tokyo, Japan) induced nephrosis rat model fed a high-protein diet that induced renal dysfunction and tubulointerstitial injury. "
09/01/2020 - "Ibrolipim, a specific lipoprotein lipase activator, has been proved to reduce hyperglycemia and hyperlipidemia, suppress renal lipid deposition, and also protect renal damage. "

02/01/2006 - "However, the effect of NO-1886 on body weight, fat accumulation, and energy expenditure in ovariectomized (OVX) rats is not clear. "
12/01/2005 - "NO-1886 suppressed the body weight increase seen in the high-fat control group after the 8-week administration (585 +/- 39 vs 657 +/- 66 g, P < .05). "
02/01/2006 - "NO-1886 decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy. "
10/15/2011 - "In summary, the combined administration of pioglitazone and NO-1886 prevented the pioglitazone-induced body weight gains and ameliorated insulin resistance observed in high-fat fed rats. "
09/01/2006 - "Administration of NO-1886 (0.1 g/kg body weight/day) in the diet for 5 months significantly reduced atherosclerosis lesions and significantly increased plasma HDL-C and apolipoprotein A-I levels. "

02/01/2006 - "Our study indicates that the LPL-promoting agent NO-1886 may be potentially beneficial in the treatment of obesity and obesity-linked health problems in postmenopausal women."
02/01/2008 - "Administration of NO-1886 attenuated the obesity-induced hypercontractility of the colonic rings of OLETF rats. "
12/01/2003 - "However, the anti-obesity mechanism of NO-1886 has not been clearly understood. "
10/15/2011 - "The lipoprotein lipase activator NO-1886 has been shown to exert both anti-obesity and anti-insulin-resistance effects. "
02/01/2006 - "The primary aim of this study was to ascertain whether NO-1886 ameliorated obesity in OVX rats and to examine the effects on fatty acid oxidation-related enzymes. "